,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,880,2,1,,29215372,4674,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
1,880,2,1,,29215372,4674,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
2,881,2,2,,29215372,4674,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
3,894,2,1,,29215372,4674,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
4,1030,2,1,,29215372,4674,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
5,1195,1,2,,48416373,4674,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
6,1379,1,2,,29215372,4674,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
7,1452,1,1,,29215372,4674,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
8,1457,1,1,,29215372,4674,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
9,1460,1,3,,29215372,4674,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
10,1463,1,1,,29215372,4674,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
11,1467,1,3,,29215372,4674,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
12,1468,1,1,,29215372,4674,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
13,1469,1,1,,29215372,4674,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
14,1471,2,1,,29215372,4674,Inconclusive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
15,1476,2,1,,29215372,4674,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
16,1477,1,1,,29215372,4674,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
17,1478,2,1,,29215372,4674,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
18,1479,1,2,,29215372,4674,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
19,1487,1,1,,29215372,4674,Inconclusive,27436948.0,4000.0,19.9526,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
20,1490,2,1,,29215372,4674,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
21,1688,1,1,,29215372,4674,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
22,1766,1,1,,29215372,4674,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
23,1766,1,1,,29215372,4674,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
24,1768,1,1,,29215372,4674,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
25,1768,1,1,,29215372,4674,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
26,1865,1,1,,29215372,4674,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
27,1948,1,1,,29215372,4674,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
28,2101,1,1,,29215372,4674,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
29,2107,1,1,,29215372,4674,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
30,2112,1,1,,29215372,4674,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
31,2314,1,2,,29215372,4674,Inactive,32400299.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
32,2314,1,2,,29215372,4674,Inactive,32400300.0,,,,Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin,Screening,,
33,2315,1,2,,29215372,4674,Inactive,32400299.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
34,2315,1,2,,29215372,4674,Inactive,32400300.0,,,,A qHTS for Small Molecule Inhibitors of Shiga Toxin,Screening,,
35,2451,1,2,,29215372,4674,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
36,2472,1,2,,29215372,4674,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
37,2517,2,1,,144205217,4674,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
38,2528,1,2,,29215372,4674,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
39,2546,1,1,,29215372,4674,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
40,2549,1,1,,29215372,4674,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
41,2551,1,1,,29215372,4674,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
42,2662,2,1,,29215372,4674,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
43,18003,3,5,,103219240,4674,Unspecified,,,,,Bioavailability by the ratios of 14C p.o. /14C i.v. accumulated in urine at 24 hr (dose 10 mg/kg p.o.),Other,11020278.0,
44,26998,3,5,,103219240,4674,Unspecified,,,,,Inhibition of HAP dissolution was determined in 3.87 mM calcium and 2.32 mM phosphate metastable solution at 0.048 mM concentration *: p<0.05,Other,11020278.0,
45,26999,3,5,,103219240,4674,Unspecified,,,,,Inhibition of HAP dissolution was determined in 3.87 mM calcium and 2.32 mM phosphate metastable solution at 0.24 mM concentration *: p<0.05,Other,11020278.0,
46,28262,3,5,,103219240,4674,Unspecified,,,,,"Inhibition of HAP formation, by the compound (1.0 mM) absorbed, was obtained in vitro studies.*: p<0.05",Other,11020278.0,
47,28263,3,5,,103219240,4674,Unspecified,,,,,"Inhibition of HAP formation, by the compound (0.1 mM) absorbed, was obtained in vitro studies.*: p<0.05",Other,11020278.0,
48,28404,3,4,,103219240,4674,Unspecified,,,,,Apical to basolateral fluxes across Caco-2 cell monolayers at 37 degree celsius was studied.,Other,11020278.0,
49,28406,4,4,,103219240,4674,Unspecified,,,,,Basolateral to apical fluxes across Caco-2 cell monolayers at 37 degree celsius was studied.,Other,11020278.0,
50,29611,3,4,,103219240,4674,Unspecified,,,,,Bioavailability by the ratios of 14C p.o. /14C i.v. accumulated in bone at 24 hr (dose 10 mg/kg p.o.),Other,11020278.0,
51,55429,6,2,,103219240,4674,Unspecified,,,167.0,IC50,Ability to inhibit growth of Dictostelium discoideum.,Confirmatory,12086477.0,
52,67525,6,2,,103219240,4674,Unspecified,,,200.0,IC50,In vitro growth inhibition against Entamoeba histolytica,Confirmatory,14695831.0,
53,71578,6,2,,103219240,4674,Unspecified,,,941.0,IC50,"Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL",Confirmatory,14711309.0,
54,71579,6,2,,103219240,4674,Unspecified,,,62.0,IC50,"Inhibitory activity, for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release",Confirmatory,14711309.0,
55,71580,5,2,,103219240,4674,Unspecified,,,933.2539999999999,IC50,"pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using a constrained maximum TNF-alpha release of 2700 pg/mL",Confirmatory,14711309.0,
56,71581,5,2,,103219240,4674,Unspecified,,,61.6595,IC50,"pIC50 value for stimulation of TNF-alpha release in gamma-delta T cells, using individual observed maximum TNF-alpha release",Confirmatory,14711309.0,
57,72181,9,2,,103219240,4674,Active,,,0.2,IC50,Inhibitory activity against the human recombinant FPPSase (Farnesyl diphosphate) enzyme,Confirmatory,12014956.0,
58,72667,9,2,,103219240,4674,Active,,,1.9,IC50,Inhibitory activity against farnesyl Pyrophosphate Synthase was determined,Confirmatory,14613320.0,
59,72668,9,2,,103219240,4674,Active,,,0.18,Ki,Binding affinity towards farnesyl Pyrophosphate Synthase using [14C]- isopentenyl pyrophosphate as radioligand,Confirmatory,14613320.0,
60,72669,6,1,,103219240,4674,Active,,,1.8620900000000002,IC50,Inhibitory activity against farnesyl Pyrophosphate Synthase expressed as #NAME? (M),Confirmatory,14613320.0,
61,74507,9,2,,103219240,4674,Unspecified,,,180.0,IC50,Inhibitory activity against the human recombinant geranylgeranyl diphosphate synthase (GGPPSase).,Confirmatory,12014956.0,
62,93828,8,1,,103219240,4674,Unspecified,,,156.0,LD50,50% lethal dose for inhibition of KB cells growth,Confirmatory,12086478.0,
63,95765,3,4,,103219240,4674,Unspecified,,,,,Inhibition of L. donovani (Amastigotes) strain MHOM/ET/67/L82 maintained in pathogen free spleen from female golden hamsters; toxic,Other,11300872.0,
64,96034,8,1,,103219240,4674,Unspecified,,,156.0,LD50,Toxicity evaluated against human nasopharyngeal carcinoma KB cell line,Confirmatory,14695831.0,
65,117725,3,3,,103219240,4674,Unspecified,,,,,Mean reduction in parasitaemia of Plasmodium berghei ANKA suppressive test in mice (Mus musculus) (in vivo) at 25 mg/kg scheduled for 4 days,Other,14695831.0,
66,132683,6,2,,103219240,4674,Active,,,0.2,IC50,Inhibition of bone resorption in the calvaria assay of mouse,Confirmatory,12166945.0,
67,132685,6,2,,103219240,4674,Unspecified,,,100.0,IC50,Inhibition of mineralization in the calvaria assay of mouse,Confirmatory,12166945.0,
68,151353,6,2,,103219240,4674,Unspecified,,,200.0,IC50,Inhibition of Plasmodium falciparum 3D7 in erythrocytes,Confirmatory,11300872.0,
69,158550,6,2,,103219240,4674,Unspecified,,,200.0,IC50,In vitro growth inhibition against Plasmodium falciparum,Confirmatory,14695831.0,
70,184809,3,3,,103219240,4674,Unspecified,,,,,Bone resorption activity in rats.,Other,12086477.0,
71,197315,5,2,,103219240,4674,Unspecified,,,,,Effective dose for increased serum urea level rats after a treatment period of 1 hr in renal tolerability model,Other,12166945.0,
72,197319,6,2,,103219240,4674,Unspecified,,,,,Effective dose for increased radiographic bone density in young interact rats after a treatment period of 10 days,Other,12166945.0,
73,197321,6,2,,103219240,4674,Unspecified,,,,,Effective dose for increased cancellous bone area in young interact rats after a treatment period of 10 days,Other,12166945.0,
74,197323,6,2,,103219240,4674,Unspecified,,,,,Effective dose for increased cancellous bone calcium in young interact rats after a treatment period of 10 days,Other,12166945.0,
75,197465,6,2,,103219240,4674,Unspecified,,,,,Effective dose for increased cancellous bone hydroxy proline in young interact rats after a treatment period of 10 days,Other,12166945.0,
76,197478,3,3,,103219240,4674,Unspecified,,,,,Effective dose for increased mucosal permeability of perfused ileal loop in rats after a treatment period of 2 hr in intestinal tolerability model,Other,12166945.0,
77,197479,3,3,,103219240,4674,Unspecified,,,,,Effective dose for increased urinary excretion of MDH in rats after a treatment period of 14 days in renal tolerability model,Other,12166945.0,
78,208084,6,2,,103219240,4674,Unspecified,,,100.0,IC50,In vitro growth inhibition of bloodstream-form Trypanosoma brucei rhodesiense Trypomastigotes,Confirmatory,12086478.0,
79,208218,6,1,,103219240,4674,Unspecified,,,100.0,IC50,Log IC50 brucei Trypomastigotes,Confirmatory,12086478.0,
80,208225,6,2,,103219240,4674,Unspecified,,,177.0,IC50,Inhibition of Trypanosoma rhodesiense (strain STIB900) was determined using blood stream from trypomastigotes,Confirmatory,11300872.0,
81,210170,6,2,,103219240,4674,Unspecified,,,,,Effective dose after subcutaneous administration to TPTX rats for 50% reduction of hypercalcemia,Other,12166945.0,
82,210617,6,2,,103219240,4674,Active,,,35.6,IC50,Inhibition of Toxoplasma gondii tachyzoites in human foreskin fibroblast monolayer(DMEM with 10%fetal calf serum),Confirmatory,11300872.0,
83,213660,6,2,,103219240,4674,Unspecified,,,65.0,IC50,In vitro antiparasitic activity against Trypanosoma cruzi (amastigotes),Confirmatory,11277521.0,
84,214469,6,2,,103219240,4674,Unspecified,,,60.0,IC50,Inhibition of Trypanosoma cruzi Amastigotes was determined in Vero cells culture and fetal calf serum,Confirmatory,11300872.0,
85,221770,8,1,,103219240,4674,Active,,,5.66,EC50,Effective concentration to activate gammadelta T cells,Confirmatory,12383012.0,
86,231757,3,3,,103219240,4674,Unspecified,,,,,Ratio of calvaria mineralization to calvaria bone resorption,Other,12166945.0,
87,235219,3,5,,103219240,4674,Unspecified,,,,,Therapeutic index measured as the ratio of LD50 (KB cells) to IC50 (T.b. rhodesiense),Other,12086478.0,
88,235770,3,3,,103219240,4674,Unspecified,,,,,Therapeutic ratio comparing nephrotoxic potential versus bone antiresorptive potency ( reciprocal of ED50 (TPTX assay) / the total urinary malate dehydrogenase excretion),Other,12166945.0,
89,238395,9,2,,103219240,4674,Unspecified,,,50.6,Ki,Inhibition of hypoxanthine-guanine phosphoribosyltransferase (TcHPRT),Confirmatory,15357980.0,
90,238531,7,2,,103219240,4674,Active,,,0.19,Ki,Binding affinity towards Farnesyl diphosphate synthase from leishmania major,Confirmatory,15828834.0,
91,244679,3,4,,103219240,4674,Unspecified,,,,,Therapeutic index (TI) value as ratio of lethal dose (LD50) to the inhibitory concentration (IC50),Other,15857119.0,
92,246048,6,3,,103219240,4674,Active,,,43.0,EC50,Effective concentration against human Gamma delta T cells,Confirmatory,15828834.0,
93,247940,6,2,,103219240,4674,Unspecified,,,167.0,IC50,Inhibitory concentration against Dictyostelium discoideum cell growth,Confirmatory,15828834.0,
94,248139,8,1,,103219240,4674,Active,,,1.6,IC50,In vitro inhibitory concentration against bone resorption in 17 day old fetal mouse metatarsals,Confirmatory,15828834.0,
95,248772,6,2,,103219240,4674,Active,,,38.0,IC50,In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells),Confirmatory,15857119.0,
96,249161,8,1,,103219240,4674,Unspecified,,,156.0,LD50,Lethal dose required to inhibit the growth of human KB (nasopharyngeal carcinoma) cell line,Confirmatory,15857119.0,
97,270722,6,2,,103219240,4674,Unspecified,,,141.0,IC50,Antiproliferative activity against human MCF7 cell line by MTT assay,Confirmatory,16970405.0,
98,270723,6,2,,103219240,4674,Unspecified,,,71.8,IC50,Antiproliferative activity against human NCI-H460 cell line by MTT assay,Confirmatory,16970405.0,
99,270724,6,2,,103219240,4674,Unspecified,,,408.0,IC50,Antiproliferative activity against human SF-268 cell line by MTT assay,Confirmatory,16970405.0,
100,270725,6,2,,103219240,4674,Active,,,33.6,IC50,Antiproliferative activity against rat 13762 cell line,Confirmatory,16970405.0,
101,275054,3,3,,103219240,4674,Unspecified,,,,,Antibacterial activity against Escherichia coli W3110,Other,17149863.0,
102,318593,10,2,,103219240,4674,Active,215274250.0,2224.0,,IC50,Inhibition of human recombinant FPPS expressed in Escherichia coli BL21,Confirmatory,18327899.0,
103,318594,10,2,,103219240,4674,Active,215274250.0,2224.0,,IC50,Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins,Confirmatory,18327899.0,
104,318595,3,3,,103219240,4674,Unspecified,,,,,Inhibition of bone resorption in rat assessed as phosphate,Other,18327899.0,
105,328053,3,4,,103219240,4674,Inactive,,,,,Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage at 200 nM,Other,17630285.0,
106,328054,3,4,,103219240,4674,Inactive,,,,,Inhibition of Escherichia coli F plasmid TraI relaxase Y16F mutant assessed as oriT ssDNA cleavage at 200 nM,Other,17630285.0,
107,328055,8,1,,103219240,4674,Unspecified,,,10000.0,EC50,Inhibition of conjugate DNA transfer between tetracycline-resistant F plasmid positive Escherichia coli JS10 to streptomycin-resistant F plasmid deficient Escherichia coli JS4,Confirmatory,17630285.0,
108,328056,8,1,,103219240,4674,Unspecified,,,10000.0,EC50,Cytotoxicity against tetracycline-resistant F plasmid positive Escherichia coli JS10,Confirmatory,17630285.0,
109,328057,8,1,,103219240,4674,Unspecified,,,10000.0,EC50,Cytotoxicity against streptomycin-resistant F plasmid deficient Escherichia coli JS4,Confirmatory,17630285.0,
110,348326,6,2,,103219240,4674,Unspecified,,,,,"Antiresorptive activity in thyroidparathyroidectomized sc dosed rat assessed as inhibition of 1,25-dihydroxyvitamin D3-induced hypercalcemia",Other,17870210.0,
111,391371,11,2,,103219240,4674,Unspecified,6831549.0,9453.0,181.97,IC50,Inhibition of human recombinant geranylgeranyl diphosphate synthase,Confirmatory,18800762.0,
112,485281,1,1,,29215372,4674,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
113,485290,1,1,,29215372,4674,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
114,492961,1,1,,29215372,4674,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
115,492967,1,2,,92217723,4674,Inactive,47566732.0,,,,A screen for compounds that inhibit the CapD enzyme of Bacillus anthracis,Other,,
116,496819,4,2,,103219240,4674,Unspecified,,,200.0,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
117,496826,4,2,,103219240,4674,Unspecified,,,200.0,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
118,504327,1,1,,29215372,4674,Inconclusive,153791535.0,2648.0,25.1189,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
119,504332,1,1,,29215372,4674,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
120,504749,1,3,,29215372,4674,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
121,504749,1,3,1.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
122,504749,1,3,2.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
123,504749,1,3,3.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
124,504749,1,3,4.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
125,504749,1,3,5.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
126,504749,1,3,6.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
127,504749,1,3,7.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
128,504749,1,3,8.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
129,504749,1,3,9.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
130,504749,1,3,10.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
131,504749,1,3,11.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
132,504749,1,3,12.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
133,504749,1,3,13.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
134,504749,1,3,14.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
135,504749,1,3,15.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
136,504749,1,3,16.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
137,504749,1,3,17.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
138,504749,1,3,18.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
139,504749,1,3,19.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
140,504749,1,3,20.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
141,504749,1,3,21.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
142,504749,1,3,22.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
143,504749,1,3,23.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
144,504749,1,3,24.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
145,504749,1,3,25.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
146,504749,1,3,26.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
147,504749,1,3,27.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
148,504749,1,3,28.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
149,504749,1,3,29.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
150,504749,1,3,30.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
151,504749,1,3,31.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
152,504749,1,3,32.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
153,504749,1,3,33.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
154,504749,1,3,34.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
155,504749,1,3,35.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
156,504749,1,3,36.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
157,504749,1,3,37.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
158,504749,1,3,38.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
159,504749,1,3,39.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
160,504749,1,3,40.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
161,504749,1,3,41.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
162,504749,1,3,42.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
163,504749,1,3,43.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
164,504749,1,3,44.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
165,504749,1,3,45.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
166,504749,1,3,46.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
167,504749,1,3,47.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
168,504749,1,3,48.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
169,504749,1,3,49.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
170,504749,1,3,50.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
171,504749,1,3,51.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
172,504749,1,3,52.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
173,504749,1,3,53.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
174,504749,1,3,54.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
175,504749,1,3,55.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
176,504749,1,3,56.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
177,504749,1,3,57.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
178,504749,1,3,58.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
179,504749,1,3,59.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
180,504749,1,3,60.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
181,504749,1,3,61.0,29215372,4674,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
182,504832,1,1,,29215372,4674,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
183,504834,1,1,,29215372,4674,Inactive,,,4.2562,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
184,504847,1,1,,29215372,4674,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
185,504865,1,1,,29215372,4674,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
186,540209,4,3,,103219240,4674,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
187,540210,4,3,,103219240,4674,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
188,540212,4,3,,103219240,4674,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
189,540213,4,3,,103219240,4674,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
190,567091,2,6,,103219240,4674,Unspecified,,,,,Drug absorption in human assessed as human intestinal absorption rate,Other,21112128.0,
191,575994,4,2,,103219240,4674,Unspecified,,,200.0,IC50,Antimalarial activity against Plasmodium berghei NK65 infected in human HepG2 cells after 48 hrs by RT-PCR,Confirmatory,20457823.0,
192,575995,2,1,,103219240,4674,Inconclusive,,,,TC50,Cytotoxicity against human HepG2 cells after 22 hrs,Confirmatory,20457823.0,
193,588209,2,3,,103219240,4674,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
194,588210,2,4,,103219240,4674,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
195,588214,2,3,,103219240,4674,Active,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
196,588215,2,3,,103219240,4674,Active,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
197,588216,2,3,,103219240,4674,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
198,588217,2,3,,103219240,4674,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
199,588218,2,3,,103219240,4674,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
200,588219,2,3,,103219240,4674,Active,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
201,588579,1,1,,29215372,4674,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
202,588834,2,1,,144205217,4674,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
203,602332,1,1,,29215372,4674,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
204,624030,1,2,,29215372,4674,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
205,624031,1,2,,29215372,4674,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
206,624032,1,2,,29215372,4674,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
207,624044,1,2,,29215372,4674,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
208,624170,1,1,,29215372,4674,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
209,624172,1,1,,29215372,4674,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
210,624173,1,3,,29215372,4674,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
211,624296,1,1,,29215372,4674,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
212,624297,1,1,,29215372,4674,Inactive,7705682.0,51053.0,13.3359,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
213,624349,1,2,,92309049,4674,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
214,625279,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
215,625280,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
216,625281,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
217,625282,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
218,625283,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
219,625284,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
220,625285,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
221,625286,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
222,625287,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
223,625288,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
224,625289,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
225,625290,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
226,625291,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
227,625292,1,3,,103219240,4674,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
228,651631,4,1,,144205217,4674,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
229,651632,4,1,,144205217,4674,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
230,651633,4,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
231,651634,4,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
232,651828,1,2,,92309049,4674,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
233,652048,1,2,,144205217,4674,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
234,652051,1,1,,144205217,4674,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
235,678712,1,8,,103219240,4674,Inconclusive,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
236,678713,1,8,,103219240,4674,Inconclusive,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
237,678714,1,8,,103219240,4674,Inconclusive,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
238,678715,1,8,,103219240,4674,Inconclusive,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
239,678716,1,8,,103219240,4674,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
240,678717,1,8,,103219240,4674,Inconclusive,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
241,678721,1,5,,103219240,4674,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
242,678722,1,5,,103219240,4674,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
243,686978,1,1,,144205217,4674,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
244,686979,1,1,,144205217,4674,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
245,689987,3,5,,103219240,4674,Active,215274250.0,2224.0,0.2,IC50,Inhibition of recombinant human FPPS expressed in Escherichia coli by scintillation counting,Confirmatory,21780776.0,
246,689988,1,2,,103219240,4674,Unspecified,,,,,Inhibition of bone resorption in rat,Other,21780776.0,
247,720516,2,1,,144205217,4674,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
248,720532,1,1,,144205217,4674,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
249,720533,1,1,,144205217,4674,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
250,720552,2,1,,144205217,4674,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
251,720634,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
252,720635,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
253,720637,2,1,,144205217,4674,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
254,720641,1,2,,92309049,4674,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
255,720674,2,2,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
256,720675,2,2,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
257,720678,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
258,720679,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
259,720680,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
260,720681,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
261,720682,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
262,720683,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
263,720684,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
264,720685,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
265,720686,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
266,720687,2,2,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
267,720691,4,1,,144205217,4674,Inactive,311348376.0,2908.0,3.378,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
268,720692,3,1,,144205217,4674,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
269,720693,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
270,720717,1,3,,92309049,4674,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
271,720719,2,1,,144205217,4674,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
272,720725,2,1,,144205217,4674,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
273,743012,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
274,743014,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
275,743015,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
276,743033,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
277,743035,2,1,,144205217,4674,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
278,743036,2,1,,144205217,4674,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
279,743040,3,1,,144205217,4674,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
280,743041,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
281,743042,3,1,,144205217,4674,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
282,743053,2,1,,144205217,4674,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
283,743054,2,1,,144205217,4674,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
284,743063,2,1,,144205217,4674,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
285,743064,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
286,743065,3,1,,144205217,4674,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
287,743066,3,1,,144205217,4674,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
288,743067,2,1,,144205217,4674,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
289,743069,2,1,,144205217,4674,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
290,743074,2,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
291,743075,2,1,,144205217,4674,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
292,743077,2,1,,144205217,4674,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
293,743078,2,1,,144205217,4674,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
294,743079,3,1,,144205217,4674,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
295,743080,3,1,,144205217,4674,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
296,743081,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
297,743083,3,1,,144205217,4674,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
298,743084,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
299,743085,3,1,,144205217,4674,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
300,743086,3,1,,144205217,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
301,743091,2,1,,144205217,4674,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
302,743094,3,1,,144205217,4674,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
303,743122,2,1,,144205217,4674,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
304,743139,2,1,,144205217,4674,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
305,743140,2,1,,144205217,4674,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
306,743191,3,1,,170464689,4674,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
307,743194,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
308,743199,2,1,,170464689,4674,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
309,743202,4,1,,170464689,4674,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
310,743203,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
311,743209,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
312,743210,4,1,,170464689,4674,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
313,743211,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
314,743212,3,1,,170464689,4674,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
315,743213,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
316,743215,3,1,,170464689,4674,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
317,743217,3,1,,170464689,4674,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
318,743218,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
319,743219,3,1,,170464689,4674,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
320,743220,3,1,,170464689,4674,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
321,743221,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
322,743222,3,1,,170464689,4674,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
323,743223,3,1,,170464689,4674,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
324,743224,3,1,,170464689,4674,Inconclusive,,,0.0017,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
325,743225,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
326,743226,2,1,,170464689,4674,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
327,743227,2,1,,170464689,4674,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
328,743228,3,1,,170464689,4674,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
329,743239,2,1,,170464689,4674,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
330,743240,2,1,,170464689,4674,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
331,743241,2,1,,170464689,4674,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
332,743242,2,1,,170464689,4674,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
333,743244,1,1,,144205217,4674,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
334,758721,1,1,,103219240,4674,Inactive,,,,,Inhibition of human osteoclast-mediated type 1 bone collagen degradation assessed as release of europium-labeled collagen fragments at 0.1 uM after 7 days by time-resolved fluorescence assay,Other,23748153.0,
335,758723,1,1,,103219240,4674,Inactive,,,,,Proapoptotic activity in human osteoclasts at 10 uM after 7 days using Hoechst 33258 staining,Other,23748153.0,
336,758724,1,1,,103219240,4674,Active,,,,,Induction of apoptosis in human osteoclasts at 100 uM after 7 days using Hoechst 33258 staining,Other,23748153.0,
337,758725,1,1,,103219240,4674,Active,,,,,Antiosteoclast activity in human PBMC assessed as reduction of osteoclasts formation by measuring TRAcP positive multinucleated cells at 10 uM after 7 days,Other,23748153.0,
338,758727,1,1,,103219240,4674,Unspecified,,,,,Cytotoxicity against mouse L929 cells assessed as reduction of cell viability after 72 hrs by neutral-red uptake assay,Other,23748153.0,
339,1079931,1,1,,103219240,4674,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
340,1079932,1,1,,103219240,4674,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
341,1079933,1,1,,103219240,4674,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
342,1079934,1,1,,103219240,4674,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
343,1079935,1,1,,103219240,4674,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
344,1079936,1,1,,103219240,4674,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
345,1079937,1,1,,103219240,4674,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
346,1079938,1,1,,103219240,4674,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
347,1079939,1,1,,103219240,4674,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
348,1079940,1,1,,103219240,4674,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
349,1079941,1,1,,103219240,4674,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
350,1079942,1,1,,103219240,4674,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
351,1079943,1,1,,103219240,4674,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
352,1079944,1,1,,103219240,4674,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
353,1079945,1,1,,103219240,4674,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
354,1079946,1,1,,103219240,4674,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
355,1079947,1,1,,103219240,4674,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
356,1079948,1,1,,103219240,4674,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
357,1079949,1,1,,103219240,4674,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
358,1117298,1,2,,170464689,4674,Inactive,,,5.6234,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
359,1117301,1,2,,170464689,4674,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
360,1117302,1,2,,170464689,4674,Inactive,,,12.5893,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
361,1117303,1,2,,170464689,4674,Inactive,,,2.52,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
362,1117304,1,2,,170464689,4674,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
363,1117305,1,2,,170464689,4674,Inactive,,,8.9125,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
364,1117310,1,1,,170464689,4674,Inactive,,,5.62341,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
365,1117311,1,1,,170464689,4674,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
366,1117312,1,1,,170464689,4674,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
367,1117314,1,1,,170464689,4674,Inactive,,,8.912510000000001,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
368,1117315,1,1,,170464689,4674,Inactive,,,12.5893,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
369,1117318,1,1,,170464689,4674,Inactive,,,2.51189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
370,1117326,1,1,,170464689,4674,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
371,1117329,1,1,,170464689,4674,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
372,1117336,1,1,,170464689,4674,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
373,1117340,1,1,,170464689,4674,Inactive,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
374,1117341,1,1,,170464689,4674,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
375,1117342,1,1,,170464689,4674,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
376,1117343,1,1,,170464689,4674,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
377,1117346,1,1,,170464689,4674,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
378,1159509,1,1,,170464689,4674,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
379,1159515,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
380,1159516,1,1,,170464689,4674,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
381,1159517,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
382,1159518,1,1,,170464689,4674,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
383,1159519,1,1,,170464689,4674,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
384,1159520,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
385,1159521,1,1,,170464689,4674,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
386,1159523,1,1,,170464689,4674,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
387,1159525,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
388,1159526,1,1,,170464689,4674,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
389,1159527,1,1,,170464689,4674,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
390,1159528,1,1,,170464689,4674,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
391,1159529,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
392,1159531,1,1,,170464689,4674,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
393,1159551,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
394,1159552,1,1,,170464689,4674,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
395,1159553,2,1,,170464689,4674,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
396,1159555,1,1,,170464689,4674,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
397,1159614,1,2,,170464689,4674,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
398,1159620,1,1,,103219240,4674,Active,,,,,Summary of drug indications.,Other,,
399,1224834,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
400,1224835,1,1,,170464689,4674,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
401,1224836,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
402,1224837,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
403,1224838,1,1,,170464689,4674,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
404,1224839,1,1,,170464689,4674,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
405,1224840,3,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
406,1224841,3,1,,170464689,4674,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
407,1224842,3,1,,170464689,4674,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
408,1224843,1,1,,170464689,4674,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
409,1224844,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
410,1224845,1,1,,170464689,4674,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
411,1224846,1,1,,170464689,4674,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
412,1224847,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
413,1224848,3,1,,170464689,4674,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
414,1224849,3,1,,170464689,4674,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
415,1224857,2,1,,170464689,4674,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
416,1224859,2,1,,170464689,4674,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
417,1224867,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
418,1224868,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
419,1224869,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
420,1224870,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
421,1224871,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
422,1224872,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
423,1224873,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
424,1224874,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
425,1224875,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
426,1224876,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
427,1224877,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
428,1224878,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
429,1224879,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
430,1224880,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
431,1224881,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
432,1224882,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
433,1224883,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
434,1224884,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
435,1224885,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
436,1224886,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
437,1224887,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
438,1224888,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
439,1224889,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
440,1224890,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
441,1224892,1,1,,170464689,4674,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
442,1224893,1,1,,170464689,4674,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
443,1224894,1,1,,170464689,4674,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
444,1224895,1,1,,170464689,4674,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
445,1224896,1,1,,170464689,4674,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
446,1224905,2,1,,92217723,4674,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
447,1224905,2,1,,92217723,4674,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
448,1224905,2,1,,92309049,4674,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
449,1224905,2,1,,92309049,4674,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
450,1226178,1,1,,103219240,4674,Unspecified,,,,,"Half life in human plasma at 1 mg/kg, iv",Other,25893039.0,
451,1259241,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
452,1259242,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
453,1259243,1,1,,170464689,4674,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
454,1259244,1,1,,170464689,4674,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
455,1259247,1,1,,170464689,4674,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
456,1259248,1,1,,170464689,4674,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
457,1259310,1,1,,321946488,4674,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
458,1259344,1,1,,144205217,4674,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
459,1259355,1,1,,144205217,4674,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
460,1259356,1,1,,144205217,4674,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
461,1259364,1,1,,170464689,4674,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
462,1259365,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
463,1259366,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
464,1259367,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
465,1259368,1,1,,170464689,4674,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
466,1259369,1,1,,170464689,4674,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
467,1259370,2,2,,124599993,4674,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
468,1259370,2,2,,124599993,4674,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
469,1259370,2,2,,124599993,4674,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
470,1259377,1,1,,170464689,4674,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
471,1259378,1,1,,170464689,4674,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
472,1259379,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
473,1259380,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
474,1259381,1,1,,170464689,4674,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
475,1259382,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
476,1259383,1,1,,170464689,4674,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
477,1259384,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
478,1259385,1,1,,170464689,4674,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
479,1259386,1,1,,170464689,4674,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
480,1259387,1,1,,170464689,4674,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
481,1259388,1,1,,170464689,4674,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
482,1259390,1,1,,170464689,4674,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
483,1259391,1,1,,170464689,4674,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
484,1259392,1,1,,170464689,4674,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
485,1259393,1,1,,170464689,4674,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
486,1259394,1,1,,170464689,4674,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
487,1259395,1,1,,170464689,4674,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
488,1259396,1,1,,170464689,4674,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
489,1259400,1,1,,170464689,4674,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
490,1259401,1,1,,170464689,4674,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
491,1259402,1,1,,170464689,4674,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
492,1259403,1,1,,170464689,4674,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
493,1259404,1,1,,170464689,4674,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
494,1259416,1,2,,340083112,4674,Inactive,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
495,1259421,1,1,,340083112,4674,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
496,1259423,1,2,,354881875,4674,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
